Marea Therapeutics has raised USD 190 million in Series A and B rounds led by Third Rock Ventures and Sofinnova Investments, respectively. Other investors include Forbion, Perceptive Xontogeny Venture Fund, venBio, Alpha Wave Global, Omega Funds, and Surveyor Capital.
The funds acquired will be used to develop the company’s MAR001 Phase II program, which is indicated for cardiometabolic diseases, and to progress extra pipeline programs.
Marea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing small molecules to treat cardiology and blood-related conditions. Its lead candidate, MAR-001, targets ANGPTL4, a protein highly expressed in adipose tissue, potentially providing a novel method of treatment for cardiometabolic diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.